Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes

Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression

(2012) Jean-Philippe Cosse et al.   Anti-Cancer Agents in Medicinal Chemistry

Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways

(2011) Nadine Rohwer et al.   DRUG RESISTANCE UPDATES

HIF-1 as a Target for Cancer Chemotherapy, Chemosensitization and Chemoprevention

(2011) Elena Monti et al.   Current Molecular Pharmacology

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia

(2010) H. J. M. de Jonge et al.   BLOOD

Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia

(2010) George Deeb et al.   LEUKEMIA RESEARCH

Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer

(2010) Sanghui Park et al.   LUNG CANCER

Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma

(2010) Xinhua Liang et al.   ORAL ONCOLOGY

Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells

(2009) A. K. Ghosh et al.   BLOOD

Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma

(2009) Gordana Đorđević et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome

(2008) Jiang Lin et al.   LEUKEMIA RESEARCH

Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

(2008) R. Sullivan et al.   MOLECULAR CANCER THERAPEUTICS